Diversified life-science + diagnostics conglomerate. Cytiva/Pall bioprocessing gives Manufacture-layer exposure; Beckman/SCIEX/Leica give Measure exposure. Paid on volume across the whole competition.
Research snapshot · Not reviewed
DHRDanaher
Diagnostics + life-science consumables
Open DHR in Robinhood ↗Conviction●○○○○1 of 5
Research target—Snapshot target
Thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap$140.09BSnapshot value
Bioprocess cycle recovery (consumables growing ~10% YoY post-destocking); Masimo-adjacent acquisition expands monitoring; Danaher Business System margin execution.
Integration risk from acquisition strategy; bioprocess cyclicality (2023-24 destocking redux); segment dilution — bioprocess is a tailwind, not the whole thesis.
needs X/Reddit sentiment sweep
Snapshot · Not reviewed🟢 Lean-Bull · ins-$0.2M · 13F 13+/12- · short↑0.26
Snapshot · Not reviewed